PROCEPT BIOROBOTICS CORPORATION - COMMON STOCK

PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million

08 Jan 2024 16:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City

13 Nov 2023 15:03:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

01 Nov 2023 15:02:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

16 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

The National Institute for Health and Care Excellence Endorses Aquablation® Therapy with "Standard Arrangements" Recommendation

12 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics Announces New Corporate Headquarters in San Jose

20 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer

12 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan

22 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston

17 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

NorthShore University HealthSystem offers expanded access to treat most common prostate ailment

16 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

PROCEPT BioRobotics Corporation Announces Pricing of Upsized Offering of Common Stock

01 Aug 2023 21:10:39 By Nasdaq GlobeNewswire

PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock

01 Aug 2023 15:06:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics® Reports Second Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

27 Jul 2023 06:00:01 By Nasdaq GlobeNewswire

PROCEPT BioRobotics to Report Second Quarter 2023 Financial Results on July 27, 2023

11 Jul 2023 15:03:00 By Nasdaq GlobeNewswire

Five-Year Data from the WATER II Study Demonstrate Aquablation Therapy Delivers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms while Preserving Sexual Function in Men with Large Prostates

28 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics Reports First Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

27 Apr 2023 06:00:01 By Nasdaq GlobeNewswire

PROCEPT BioRobotics to Report First Quarter 2023 Financial Results on April 27, 2023 and Present at the Bank of America 2023 Health Care Conference in Las Vegas

05 Apr 2023 15:03:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates

03 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

PROCEPT BioRobotics Corp. Announces Investor Event at 2023 AUA Annual Meeting in Chicago

30 Mar 2023 15:05:01 By Nasdaq GlobeNewswire

Aquablation Therapy is the first surgical robotics system to receive a MedTech Innovation Briefing (MIB) from the National Institute for Health Care Excellence

07 Mar 2023 06:00:01 By Nasdaq GlobeNewswire